New methods predict drug interactions using drug co-medication patterns and graph matching.
problem Predicting adverse drug reactions from drug combinations.
method Developed novel kernels over drug combinations using support vector machines and graph matching to measure similarities.
result Achieved an AUC of 0.912 on a real-world dataset.
Generative model designs drug combinations for improved efficacy and reduced side effects.
problem Designing effective drug combinations to overcome resistance and reduce side effects.
method Developed a deep generative model using HVGAE and a novel reward system.
result Network-principled drug combinations show reduced toxicity and potential for new strategies.
A neural network predicts drug interactions using attention mechanisms.
problem Predicting drug-drug interactions from massive combinations of drugs.
method Siamese self-attention multi-modal neural network integrating drug characteristics.
result The model achieves AUPR scores ranging from 0.77 to 0.92 on various benchmark datasets.
Models predict drug interactions with high accuracy.
problem Detecting drug-drug interactions to prevent medical injuries.
method Artificial neural networks and graph similarity measures.
result Models achieve high accuracy in predicting drug interactions.
Drug resistance is still a major challenge in cancer therapy. Drug combination is expected to overcome drug resistance. However, the number of possible drug combinations is enormous, and thus it is infeasible to experimentally screen all effective drug combinations considering the limited resources. Therefore, computat…
Study improves drug synergy prediction using ensemble learning.
problem Predicting drug synergy in complex diseases.
method Investigated different compound representations and proposed an ensemble model.
result Ensemble model outperforms baseline models.
Drug similarity has been studied to support downstream clinical tasks such as inferring novel properties of drugs (e.g. side effects, indications, interactions) from known properties. The growing availability of new types of drug features brings the opportunity of learning a more comprehensive and accurate drug similar…
HAMN combines CF models to improve drug repositioning.
problem Efficient drug repositioning with cold start problem.
method Hybrid Attentional Memory Network (HAMN) integrating memory and attention mechanisms.
result HAMN outperforms other models in drug repositioning tasks.
A new drug embedding method using hierarchical drug relations and chemical structures.
problem Learning accurate drug representations from chemical structures and hierarchies.
method Semi-supervised drug embedding using VAE in hyperbolic space.
result The method accurately places drugs in a hierarchy and predicts side-effects.
SDF-Bayes finds safe drug combinations safely, balancing optimism and caution.
problem Finding safe drug combinations in clinical trials with multiple drugs and patient heterogeneity.
method SDF-Bayes uses Bayesian statistics to choose the most likely MTD while ensuring safety constraints.
result SDF-Bayes outperforms existing methods in both accuracy and safety for drug combination trials.
Develops a scalable model for drug combination prediction in cancer.
problem Accurate prediction of drug combinations for cancer treatment.
method Permutation invariant multi-output Gaussian Processes with variational approximation and deep generative model.
result Model efficiently borrows information across drug combinations and provides uncertainty quantification.
CardiGraphormer uses SSL and GNNs to improve drug discovery.
problem Challenges in drug discovery due to combinatorial chemical space and limited approved drugs.
method Combines self-supervised learning, Graph Neural Networks, and Cardinality Preserving Attention.
result Enhanced predictive performance and interpretability in drug discovery.
Generative model tailors anticancer drugs based on transcriptomic data.
problem Designing effective anticancer drugs considering genetic profiles.
method RL framework using pretrained VAEs to generate compounds conditioned on transcriptomic data.
result Generative model produces molecules with high predicted inhibitory effects.
Bayesian model for cancer drug studies maps dose-response curves.
problem Mapping dose-response curves in cancer drug studies.
method Bayesian Tensor Filtering (BTF) with low-dimensional embeddings and structured shrinkage priors.
result BTF outperforms state-of-the-art methods in cancer drug studies.
Graph-augmented CNN predicts drug interactions with high accuracy.
problem Predicting drug-drug interactions (DDIs) with high accuracy.
method Combining graph CNN with an attentive pooling network to extract structural relations between drug pairs.
result Desirable performance with ROC 0.988, F1-score 0.956, and AUPR 0.986.
Study reveals similarities in knowledge flows between pharmaceutical and AI industries.
problem Understanding the dynamics of drug pipelines in global pharmaceutical industry.
method Multilayer network analysis of drug pipeline, global supply chain, and ownership data.
result Proven similarities in knowledge flows between pharmaceutical and AI industries.
POEM predicts drug properties without tuning, outperforming other methods.
problem Predicting drug properties from molecular structures efficiently.
method POEM combines multiple molecular representations without hyperparameter tuning.
result POEM outperforms industry-standard methods across 17 tasks.
Dr.S recommends cancer drugs based on genomic data.
problem Personalizing cancer treatments using genomic information.
method Machine learning to identify optimal drug-gene associations.
result Developed a Drug Recommendation System (Dr.S) for cancer cell lines.
Deep Rule Forests identifies drug-drug and drug-disease interactions causing AKI.
problem Identifying drug-drug and drug-disease interactions leading to AKI.
method Deep Rule Forests (DRF) algorithm discovering rules from multilayer tree models.
result DRF model outperforms other algorithms in prediction accuracy and interpretability.
Recent progress in deep learning is revolutionizing the healthcare domain including providing solutions to medication recommendations, especially recommending medication combination for patients with complex health conditions. Existing approaches either do not customize based on patient health history, or ignore existi…
The use of drug combinations, termed polypharmacy, is common to treat patients with complex diseases and co-existing conditions. However, a major consequence of polypharmacy is a much higher risk of adverse side effects for the patient. Polypharmacy side effects emerge because of drug-drug interactions, in which activi…
Drug-drug interactions (DDIs) are a major cause of preventable hospitalizations and deaths. Predicting the occurrence of DDIs helps drug safety professionals allocate investigative resources and take appropriate regulatory action promptly. Traditional DDI prediction methods predict DDIs based on the similarity between …
Model learns disease self-representations for drug repositioning.
problem Drug repositioning for disease treatment.
method Enforces proximity in disease self-representations to preserve human phenome network structure.
result Method outperforms state-of-the-art approaches and produces biologically interpretable disease self-representations.
TIP model improves POSE prediction with less resources.
problem Predicting polypharmacy side effects from drug-protein interactions.
method TIP model operates on three subgraphs for progressive representation learning.
result Improves accuracy by 7%+, time efficiency by 83imes, and space efficiency by 3imes. We present the Network-based Biased Tree Ensembles (NetBiTE) method for drug sensitivity prediction and drug sensitivity biomarker identification in cancer using a combination of prior knowledge and gene expression data. Our devised method consists of a biased tree ensemble that is built according to a probabilistic bi…
Predict drug-drug side effects using co-attention neural network.
problem Early detection of polypharmacy side effects in drug combinations.
method Co-attention neural network architecture for DDI prediction.
result State-of-the-art results on predicting side effects from drug types and structures.
Currently, approximately 30% of epileptic patients treated with antiepileptic drugs (AEDs) remain resistant to treatment (known as refractory patients). This project seeks to understand the underlying similarities in refractory patients vs. other epileptic patients, identify features contributing to drug resistance acr…
Identification of high affinity drug-target interactions is a major research question in drug discovery. Proteins are generally represented by their structures or sequences. However, structures are available only for a small subset of biomolecules and sequence similarity is not always correlated with functional similar…
Study uses machine learning to analyze state drug policies and reduce overdose deaths.
problem Epidemic opioid overdose rates and ineffective state-level policies.
method Hierarchical clustering of 138 binomial variables to generate policy bundles, then regression analysis.
result Balancing certain policies leads to reduced overdose deaths, but only after second year.
New disease drug trials use ML to predict best therapy.
problem Developing new drugs faster than usual clinical trials.
method Use Neural Network to predict drug effects from patient data.
result Neural Network outperforms traditional placebo-controlled trials.
Motivation: Analysis of relationships of drug structure to biological response is key to understanding off-target and unexpected drug effects, and for developing hypotheses on how to tailor drug thera-pies. New methods are required for integrated analyses of a large number of chemical features of drugs against the corr…
This review introduces graph kernels for chemoinformatics.
problem Quantifying similarity between molecular graphs.
method Graph kernels as a method for quantifying molecular graph similarity.
result Graph kernels have direct applications in chemoinformatics.
ChemCPA predicts cellular responses to novel drugs using transfer learning.
problem Scaling high-throughput screens to measure cellular responses for many drugs is costly and challenging.
method ChemCPA, a new encoder-decoder architecture combined with transfer learning.
result Training on existing bulk RNA HTS datasets improves generalization performance, reducing the need for extensive single-cell screens.
Chemotherapeutic response of cancer cells to a given compound is one of the most fundamental information one requires to design anti-cancer drugs. Recent advances in producing large drug screens against cancer cell lines provided an opportunity to apply machine learning methods for this purpose. In addition to cytotoxi…
The polypharmacy side effect prediction problem considers cases in which two drugs taken individually do not result in a particular side effect; however, when the two drugs are taken in combination, the side effect manifests. In this work, we demonstrate that multi-relational knowledge graph completion achieves state-o…
Improved anti-cancer drug sensitivity prediction using REFINED CNN ensemble learning.
problem Challenges in predicting anti-cancer drug sensitivity for individual cell lines.
method Using REFINED CNN, which represents high-dimensional vectors as compact 2D images with spatial correlations, and building ensembles of these models.
result Ensemble approaches significantly improve drug sensitivity prediction performance compared to single models.
Method integrates logical rules into neural multi-hop reasoning for drug repurposing.
problem Capturing long-range dependencies in biomedical data.
method Combines logical rules with neural multi-hop reasoning using reinforcement learning.
result Our method outperforms baseline methods in drug repurposing tasks.
Study improves neural network calibration for drug discovery.
problem Improper calibration of neural network predictions in drug discovery.
method Compared different metrics for model hyperparameter tuning and proposed Bayesian Linear Probing (BLP) method.
result Bayesian Linear Probing (BLP) improves model calibration and accuracy.
Automated digital twin discovery from biological data improves drug discovery and personalized medicine.
problem Developing reliable digital twins from noisy, incomplete biological data.
method Symbolic and sparse regression, Bayesian frameworks, deep learning, and large language models.
result Sparse regression generally outperforms symbolic regression, especially with Bayesian frameworks.
Recent advances in machine learning have made significant contributions to drug discovery. Deep neural networks in particular have been demonstrated to provide significant boosts in predictive power when inferring the properties and activities of small-molecule compounds. However, the applicability of these techniques …
Project analyzes drug reviews to predict ratings using machine learning.
problem Predicting drug ratings from text reviews.
method Implemented supervised machine learning algorithms with TFIDF and Count Vectors.
result Good results in predicting test data sets for popular conditions.
New method uses Riemannian geometry to quantify molecular shapes.
problem Quantifying molecular similarity for drug discovery.
method Riemannian geometry and Kähler quantization (KQMolSA).
result KQMolSA method compares well to existing shape similarity methods.
Designing a molecule with desired properties is one of the biggest challenges in drug development, as it requires optimization of chemical compound structures with respect to many complex properties. To augment the compound design process we introduce Mol-CycleGAN - a CycleGAN-based model that generates optimized compo…
hyperSBINN improves drug cardiosafety assessment by efficiently modeling cardiac action potentials.
problem Complexity and limited data in modeling cardiac effects of drugs.
method Combining meta-learning with SBINNs to solve parameterized cardiac action potential models.
result hyperSBINN outperforms traditional solvers in speed and accuracy for predicting APD90 values.
In de novo drug design, computational strategies are used to generate novel molecules with good affinity to the desired biological target. In this work, we show that recurrent neural networks can be trained as generative models for molecular structures, similar to statistical language models in natural language process…
We present a framework, which we call Molecule Deep Q-Networks (MolDQN), for molecule optimization by combining domain knowledge of chemistry and state-of-the-art reinforcement learning techniques (double Q-learning and randomized value functions). We directly define modifications on molecules, thereby ensuring 100…
Generates natural product-like compounds using GPT models.
problem Challenges in generating and evaluating natural product-like compounds.
method Trained GPT-based chemical language models on natural product dataset.
result Generated compounds have similar distribution to natural products.
Modof-pipe optimizes molecules by modifying a single site, outperforming state-of-the-art methods.
problem Improving drug candidates' properties through chemical modification.
method Deep generative model Modof over molecular graphs for molecule optimization.
result Modof-pipe achieves significant improvements in octanol-water partition coefficient and molecule similarity constraints.